WinwinGPT 即將上線,加入 Waitlist 上線搶先用!

Fate therapeutics inc

美股醫療保健

FATE 投資分析

看多重點:

  • 價值≥4
  • 股利≥2

分析結論

價值面獲得最高評分,但股利評分未超過2分,若公司開始配息,可能會有更優異的投資結果

FATE 近期報酬表現

-

Fate therapeutics inc

1.20%

同產業平均

0.11%

S&P500

與 FATE 同產業的標的表現

  • VCYT Veracyte inc
    價值 3 分趨勢 1 分波段 2 分籌碼 2 分股利 1 分
    查看更多

FATE 公司資訊

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company's platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.

FATE 股價